منابع مشابه
Busulfan disposition in children.
Children receive busulfan orally as part of myeloablative therapy before bone marrow transplantation for malignant and nonmalignant conditions. Children have been reported to have a low incidence of severe toxicity and significant rates of failure to achieve full engraftment. We evaluated the disposition of busulfan in children between 2 months and 3.6 years of age with lysosomal storage diseas...
متن کاملBusulfan disposition below the age of three: alteration in children with lysosomal storage disease.
Busulfan disposition is age-dependent with a higher clearance and a larger volume of distribution in children than in adults. The optimal dosage of busulfan needed to achieve bone marrow (BM) displacement in young children with malignant or nonmalignant disease remains to be defined. Using a gas chromatography-mass spectrometry assay, we evaluated plasma pharmacokinetics of busulfan in 33 child...
متن کاملdomestication and foreignization in children literature translation
این پایان نامه به بررسی بومی سازی و بیگانه سازی در ادبیات کودکان مخصوصا زانر فانتزی می پردازد. در این پایان نامه ترجمه 14 کتاب داستان فانتزی برای سه گروه سنی کودکان بر اساس مدل ونوتی یعنی بومی سازی و بیگانه سازی مقاسه شدندکه در نتیجه برای سه گروه سنی از هر دو استراتزی توسط مترجمان در ترجمه کلمات فرهنگی استفاده شده است.
Teniposide (VM26) Disposition in Children with Leukemia1
The clinical pharmacokinetics of teniposide (VM-26, NSC 122819) has been studied in 21 children (median age, 4.7 years) with acute lymphocytic leukemia. Teniposide was administered at a dosage of 165 mg/sq m as a 30to 60-min i.v. infusion. Patients were studied either on the first or second dosage of the drug. Plasma samples were assayed for teniposide and metab olites by high-performance liqui...
متن کاملPopulation Pharmacokinetics of Busulfan in Children: Increased Evidence for Body Surface Area and Allometric Body Weight Dosing of Busulfan in Children Running title: Population Pharmacokinetics of Busulfan in Children
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. In this article we propose new individualized busulfan dosing regimens, in order to increase safety and efficacy during busulfan therapy especially in very small children. Busulfan has a very narrow therapeutic range with higher AUC values causing a high risk of sinuosoidal obstruction syndrome...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1990
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v75.8.1723.bloodjournal7581723